Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 1

1(20.0%)

Early Phase 1

1(20.0%)

5Total

N/A(3)

Phase 1(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07530328Not ApplicableCompleted

Clinical Evaluation of Copesilcup

Role: collaborator

NCT07255521Not ApplicableNot Yet Recruiting

Prehabilitation to Improve Frailty, Function, and Quality of Life in Candidates for Hematopoietic Stem Cell Transplantation

Role: lead

NCT06556004Phase 1Unknown

Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients

Role: collaborator

NCT04979897Completed

Impact on Mental, Physical, And Cognitive Functioning of a Critical Care sTay During the COVID-19 Pandemic

Role: collaborator

NCT06256965Completed

Cardiopulmonary Bypass and Ventricular Remodeling

Role: collaborator

NCT03960164Early Phase 1Completed

Dermal Regeneration Photosynthetic Matrix

Role: collaborator

NCT02590978Not ApplicableTerminated

Early Cholecystectomy in Patients With Mild Gallstone Acute Pancreatitis

Role: lead

All 7 trials loaded